ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 716,18
0,08%
Dow Jones
43 487,83
0,78%
DAX
20 908,78
0,05%
Brent Oil
80,065
-0,19%
Bitcoin
106 820,31
3,60%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. IN8bio Inc (INAB)

  7. IN8bio Inc (INAB) Actualités

INAB

IN8bio (INAB)

IN8bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INAB
DateHeureSourceTitreSymboleSociété
06/01/202513h00GlobeNewswire Inc.IN8bio to Present at Biotech Showcase 2025 in San FranciscoNASDAQ:INABIN8bio Inc
23/12/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INABIN8bio Inc
10/12/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INABIN8bio Inc
10/12/202413h00GlobeNewswire Inc.IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual MeetingNASDAQ:INABIN8bio Inc
02/12/202413h00GlobeNewswire Inc.IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity ConferenceNASDAQ:INABIN8bio Inc
25/11/202413h00GlobeNewswire Inc.IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual MeetingNASDAQ:INABIN8bio Inc
13/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INABIN8bio Inc
12/11/202422h45Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:INABIN8bio Inc
12/11/202422h33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INABIN8bio Inc
12/11/202422h26GlobeNewswire Inc.IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:INABIN8bio Inc
12/11/202413h00GlobeNewswire Inc.IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual MeetingNASDAQ:INABIN8bio Inc
05/11/202415h00GlobeNewswire Inc.IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual MeetingNASDAQ:INABIN8bio Inc
04/11/202422h31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INABIN8bio Inc
15/10/202422h04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INABIN8bio Inc
01/10/202414h00GlobeNewswire Inc.IN8bio Announces Pricing of $12.4 Million Private PlacementNASDAQ:INABIN8bio Inc
04/09/202422h01GlobeNewswire Inc.IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid LeukemiaNASDAQ:INABIN8bio Inc
29/08/202412h05GlobeNewswire Inc.IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:INABIN8bio Inc
12/08/202423h11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INABIN8bio Inc
12/08/202414h05GlobeNewswire Inc.IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100NASDAQ:INABIN8bio Inc
08/08/202422h05GlobeNewswire Inc.IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:INABIN8bio Inc
24/06/202414h00GlobeNewswire Inc.IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceNASDAQ:INABIN8bio Inc
13/06/202422h01GlobeNewswire Inc.IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100NASDAQ:INABIN8bio Inc
03/06/202412h05GlobeNewswire Inc.IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:INABIN8bio Inc
24/05/202414h00GlobeNewswire Inc.IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024NASDAQ:INABIN8bio Inc
23/05/202423h00GlobeNewswire Inc.IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingNASDAQ:INABIN8bio Inc
14/05/202416h00GlobeNewswire Inc.IN8bio Announces Upcoming Presentation at 2024 European Hematology Association CongressNASDAQ:INABIN8bio Inc
13/05/202414h00GlobeNewswire Inc.IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024NASDAQ:INABIN8bio Inc
09/05/202422h00GlobeNewswire Inc.IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:INABIN8bio Inc
30/04/202412h05GlobeNewswire Inc.IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed GlioblastomaNASDAQ:INABIN8bio Inc
24/04/202414h00GlobeNewswire Inc.IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:INABIN8bio Inc
 Showing the most relevant articles for your search:NASDAQ:INAB

Dernières Valeurs Consultées

EU
CS
Axa
EU
HO
Thales
EU
RNO
Renault
NASDAQ
NVDA
NVIDIA
NYSE
MCD
McDonalds
EU
AF
Air FranceKLM
EU
ORA
Orange
EU
ACA
Credit Agricole
EU
CAP
Capgemini
COIN
DOGEUSD
Dogecoin
COIN
SOLUSD
Solana
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
AAPL
Apple
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés